Relmada Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Relmada Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.3%
Buyback Yield
| Total Shareholder Yield | -0.3% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
Mar 21Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 13
Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark
Jan 14Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Dec 04Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Aug 29We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
May 07We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Dec 15Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure
Oct 14Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up
Sep 14Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression
Aug 09We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely
Jul 14Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Feb 264 Clinical Catalysts On Tap For Relmada In 2022
Jan 28Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Nov 04Our First Look At Relmada Therapeutics
Jun 28We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Jun 28Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 09What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?
Jan 15
Enrollment underway in Relmada Therapeutics' late-stage depression study with REL-1017
Dec 07Relmada Therapeutics (RLMD) Investor Presentation - Slideshow
Dec 02Relmada Therapeutics (RLMD) Investor Presentation - Slideshow
Nov 16Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if RLMD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RLMD's dividend payments have been increasing.
Dividend Yield vs Market
| Relmada Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (RLMD) | n/a |
| Market Bottom 25% (US) | 1.3% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Pharmaceuticals) | 2.4% |
| Analyst forecast (RLMD) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate RLMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RLMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate RLMD's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RLMD has not reported any payouts.